This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Too Many Choices, Which Ones Work?

Prakash C. Deedwania, MD; Enrique V. Carbajal, MD

Arch Intern Med. 1993;153(3):285-288.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

MYOCARDIAL INFARCTION (MI) is a major sequela of coronary artery disease and carries an adverse prognosis for life. Each year more than 1 million Americans suffer from MI, and about 70% survive the acute event. The survivors of MI remain at risk for reinfarction and death. The subsequent prognosis of these patients is related to the extent and location of MI, left ventricular dysfunction, arrhythmia, and residual ischemia.

Several large clinical trials have been conducted in an effort to alter the prognosis after MI. These trials have evaluated effects of calcium-channel blockers,^1-12β-blockers,^13-24 nitrates,^25-27 antiplatelet therapy, antiarrhythmic drugs,^28-30 risk factor modification,^31-35 and myocardial revascularization. Of these, only a few have demonstrated beneficial effects in the period after MI. Actually, some studies^1-8,28-30 have shown deleterious effects of treatment used for secondary prevention. The results of the second Secondary Prevention Reinfarction Israel Nifedipine Trial (SPRINT 2) . . . [Full Text PDF of this Article]

Author Affiliations
Division of Cardiology Department of Medicine UCSF Program/VAMC 2615 E Clinton Ave Fresno, CA 93703

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?